Oppenheimer initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $7 price target The firm said the rating is based on its conviction for lead asset OV329 to address epilepsy disorders with validating clinical data. OV329 modulates GABA to calm seizures, and Oppenheimer sees a $1B+ potential market opportunity, the firm tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID: